## **STS** National Database<sup>™</sup>

Trusted. Transformed. Real-Time.

Society of Thoracic Surgeons

General Thoracic Surgery Database User Group Call

June 22, 2022


## GTSD User Group Call

- Welcome and Introductions
- STS Update
- AQO 2022
- PFT's
- Nodes Assessed
- User Feedback
  - Include Ticket Number/Case Number



# **STS Updates**

- Training Manual for June is posted
- Spring 2022 Analysis Results Coming Soon!
  - IQVIA implementing feedback from UAT Testers
  - Reports expected to be available by the end of this month (June)
  - Report related questions should be directed to <u>gtsdtechsupport@iqvia.com</u>
- 2022 Audit
  - Audit Notification Letters have been sent to selected sites
  - Audit Instruction Letters have been sent STS audit webpage has been updated with 2022 audit details
- GTSD Public Reporting
  - Next update is scheduled for this Summer
  - Will utilize results from Fall 2021 Harvest (July 1, 2018 June 30, 2021)
  - Questions should be directed to Sydney Clinton (<u>sclinton@sts.org</u>)



#### ADVANCES IN QUALITY & OUTCOMES: A Data Managers Meeting October 26-28, 2022 • PROVIDENCE, RHODE ISLAND







#### ADVANCES IN QUALITY & OUTCOMES: A Data Managers Meeting October 26-28, 2022 - PROVIDENCE, RHODE ISLAND

Abstract Submission Deadline: Tuesday, July 5, 2022.

Click **Submit an Abstract** on the STS AQO Website.

All authors listed on the abstract are required to submit a Disclosure Form at the time of submission. Your submission will not be listed as complete unless each author has submitted a Disclosure Form.

#### Submit an Abstract

Abstracts are now being accepted for consideration. Submissions are due on Tuesday, July 5, 2022, at 11:59 p.m. ET. Accepted submissions will be presented as e-posters, while a small number also may be selected for oral presentation. Submitted abstracts must use STS National Database Core Fields and Participating Sites Custom Fields to produce results.

#### Deadline

Tuesday, July 5, 2022, at 11:59 p.m. ET

View Abstract Guidelines

Submit Abstract





ADVANCES IN QUALITY & OUTCOMES: A Data Managers Meeting October 26–28, 2022 = PROVIDENCE, RHODE ISLAND

# AQO Registration is Open!

#### Receive Early Bird Registration Pricing through Friday, August 26.

STS MEMBER	Early Bird (August 26, 2022)	Standard
One Track	\$550	\$650
Two Tracks	\$900	\$1,100
Multi-Day (Three Tracks)	\$1,150	\$1,450
Virtual Pass	\$300	\$300
NON-MEMBER	Early Bird (August 26, 2022)	Standard
	· · · · · · · · · · · · · · · · · · ·	<b>Standard</b> \$750
One Track	(August 26, 2022)	
NON-MEMBER One Track Two Tracks Multi-Day (Three Tracks)	(August 26, 2022) \$650	\$750



#### Wednesday, October 26, 2022 – General Thoracic Session

	In Person	Virtual Pass
<ul> <li>In-person sessions with live Q&amp;A</li> </ul>	Ø	
<ul> <li>On-demand content (available mid-October)</li> </ul>	$\bigotimes$	Ø
<ul> <li>Recorded archive of in-person sessions (available mid-November)</li> </ul>	Ø	$\bigotimes$
<ul> <li>Breakfast, lunch, and refreshment breaks</li> </ul>	$\bigotimes$	
<ul> <li>Personal interactions and networking with peers</li> </ul>	$\bigotimes$	
<ul> <li>Networking Reception with speakers, vendors, and colleagues</li> </ul>	Ø	
Face-to-face time with exhibitors	$\bigotimes$	
Complete exhibitor listing	Ø	Ø
<ul> <li>Exhibit Hall giveaways and Passport to Prizes</li> </ul>	Ø	
• AQO Hot Topics Webinar (in January)	Ø	$\bigotimes$
<ul> <li>Digital conference materials (PowerPoint presentations, handouts, and case scenarios)</li> </ul>	Q	${\color{black}}$
<ul> <li>Opportunity to view and vote on your favorite e-poster</li> </ul>	Ø	$\bigotimes$
Continuing Education/CEU Credits	Ø	Ø
<ul> <li>Explore the sights and sounds of Providence, Rhode Island</li> </ul>	Q	

al Database

GTSD Preliminary Program Topics

- Audit
- Pre-Operative Evaluation or Risk Factors (Understanding PFT's, ECHO and Pharmacy)
- Lung Cancer (Path Reports, Tumor Staging, Case Scenarios)
- Esophageal Cancer (Path Reports, Tumor Staging, Case Scenarios)
- Post-Op Complications
- Quality Improvement / Using Data to Improve Outcomes
- GTSD Research
- Hiatal Hernia

• <u>Submit your questions or</u> <u>case scenarios</u> by Friday, August 16.





- Educational sessions and social events will take place at the Rhode Island Convention Center (1 Sabin St, Providence, RI 02903).
- A block of rooms have been reserved at the Omni Providence Hotel (1 West Exchange St., Providence, RI 02903). The special AQO group rate of \$259, plus state and local taxes, is guaranteed through **Tuesday, October 4**, or until the group block is sold out.
- <u>Reserve online</u>
- Call 401-598-8000. Be sure to reference "AQO" or "Advances in Quality and Outcomes."





#### STS AQO IS GOING GREEN!!!!! All materials will be posted and available for download.







# MORE PFT's Please!!!!!

**Intent/Clarification:** Indicate the FEV1 % predicted from the most recent pulmonary function test prior to procedure. Do not use values obtained more than 12 months prior to surgery. <u>Choose the highest value reported for</u> % predicted, whether or not a bronchodilator was used.

June 2022: Code the highest value reported for % predicted predicted, whether or not a bronchodilator was used. If your PFT report does not provide you with calculated percentages or only gives you the percent difference between pre/post bronchodilator both values can be calculated, not just pre-bronchodilator value as in the example above.

#### What value would you code for seq 750?

A. 93

			Pre	Bronch		Po	st-Bronch	
В.	68		<u>Actual</u>	Pred	<u>%Pred</u>	<u>Actual</u>	<u>%Pred</u>	<u>%Chng</u>
		SPIROMETRY						
<b>C</b> .	71	FVC (L)	2.11	2.89	73	2.34	80	+10
		FEV1 (L)	1.48	2.17	68	1.54	71	+4
D.	72	FEV1/FVC (%)	70	75	93	66	87	-5
		FEF 25% (L/sec)	3.13	4.67	67	3.40	72	+8
Ε.	l'm not sure							

#### What value would you code for seq 750?

А.	83	Pre-Bronch				Post Bronch			
			<u>Actual</u>	Pred	<u>%Pred</u>	<u>SD</u>	LLN	<u>Actual</u>	<u>%Chng</u>
🗡 В.	91	SPIROMETRY							
C. 74	74	FVC (L)	1.84	2.59	70	0.39	1.96	2.09	+13
	FEV1 (L)	1.49	1.99	74	0.34	1.44	1.81	+21	
D	95	FEV1/FVC (%)	81	81	99	6	70	87	+7
0. 55	55	FEV1/SVC (%)	64	77	83				
Ε.	I'm not sure	FEV6 (L)	1.84	2.42	75	0.39	1.78	2.09	+13
		FEV1/FEV6 (%)	81	83	97	6	73	87	+7
		FEV3/FVC (%)	98	106	93			100	+1

The bottom report is much easier to use as a data manager, the % predicted is given for both pre and post bronchodilator. However, if % predicted is not given it must be calculated.

Pre-Bronch: Pre-Bronch Actual/Pred

Post Bronch: Post-Bronch Actual/Pred

The predicted value which goes in the denominator will be the same pre and post and is unique to each patient. It is based on the patients age, race, height and gender.

	Pre	-Bronch			Pe	ost Bronch	
	Actual	Pred	%Pred	<u>SD</u>	LLN	Actual	%Chng
SPIROMETRY							
FVC (L)	1.84	2.59	70	0.39	1.96	2.09	+12
FEVI (L)	1.49	1.99	74	0.34	1.44	1.81	+2
FEVI/FVC (%)	81	81	.99	6	70	87	+'
FEV1/SVC (%)	64	77	83				
FEV6 (L)	1.84	2.42	75	0.39	1.78	2.09	+1
FEV1/FEV6 (%)	81	83	97	6	73	87	+
FEV3/FVC (%)	98	106	93			100	+

	Pre-Bronch			Post-Bronch		
SPIROMETRY	<u>Actual</u>	Pred	<u>%Pred</u>	<u>Actual</u>	<u>%Pred</u>	<u>%Chng</u>
FVC (L)	2.11	2.89	73	2.34	80	+10
FEV1 (L)	1.48	2.17	68	1.54	71	+4
FEV1/FVC (%)	70	75	93	66	87	-5
FEF 25% (L/sec)	3.13	4.67	67	3.40	72	+8

#### Seq 781: DLCO Lowest Predicted

Intent/Clarification: The diffusing capacity (DLCO) may be reduced, <80% predicted, in disorders such as emphysema, pulmonary fibrosis, obstructive lung disease, pulmonary embolism, pulmonary hypertension and anemia.

DLCO>120% of predicted may be seen in normal lungs, asthma, pulmonary hemorrhage, polycythemia, and left to right intracardiac shunt.

The lowest value for DLCO uncorrected should be captured. A PFT may report DLCO\_SB, DLCOcSB, DLCO/VA. The difference in the DCLO SB (simple DCLO) and the DCLOcSB is that the DCLOcSB is corrected for the hgb value. In this scenario, capture the lowest DLCO\_SB or DLCO/VA value. Do not use the DLCOcSB since it is a corrected value.

Choose the value that represents the lowest % predicted unadjusted/uncorrected DLCO.

DO NOT USE the DLCO/VA (adjusted/corrected), regardless of altitude..... (Jan 2022)

Oct 2021: Round to the nearest whole integer at entry.

Jan 2022: Capture the lowest DLCO\_SB or DLCO/VA. Values corrected for hemoglobin should not be utilized for sequence 781.

#### Seq 781: DLCO Lowest Predicted

## What value would you code for seq 781?

- A. 91
- B. 133
- C. 68
- D. 18
- E. I'm not sure

	Pre-Bronch				
	<u>Actual</u>	<u>Pred</u>	<u>%Pred</u>	<u>SD</u>	LLN
DIFFUSION					
DLCOunc (ml/min/mmHg)	17.09	18.74	91		14.37
DLCOcor (ml/min/mmHg)		18.74		•	14.37
DL/VA (ml/min/mmHg/L)	5.44	4.07	133		
VA (L)	3.14	4.60	68	0.54	3.72
IVC (L)	2.02				

### Seq 781: DLCO Lowest Predicted

What value would you code for seq 781?

Α.	85				
			Pr	e-Bronch	
Β.	83	DIFFUSION	<u>Actual</u>	<u>Pred</u>	<u>%Pred</u>
★C.	71	DLCOune (ml/min/mmHg) DLCOcor (ml/min/mmHg)	17.45	24.26 24.26	71
D.	18	DL/VA (ml/min/mmHg/L) VA (L)	4.02 4.35	4.80 5.05	83 85
E.	I'm not sure	Hgb (gm/dL)	<b>ن د</b>	12-18	65

# Lung CA NODES Assessed

When the July training manual is published, there will be additional guidance added for seq 1880.

- This does not go into effect until the date the July TM is published.
- The intent is to provide you with a preview now, so that when the July TM is published you have additional background surrounding the changes.
- This update only applies to patients that have had a mediastinoscopy prior to lung resection (currently about 5% of cases)

The problem: Some institutions have begun issuing synoptic pathology reports where lymph nodes harvested prior to the surgical resection are included in the pathology report for the surgical procedure. They include statements such as:

'SYNOPTIC REPORTING LUNG 8<sup>th</sup> edition' OR

'Comment(s): This incorporates lymph nodes from the previous or prior...'

Prior to 5.21, guidance was to capture the pathological stage that was indicated on the pathology report for the index procedure being abstracted. However, synoptic reports required a rethinking of that guidance.

The STS formed a subgroup of surgeons that specifically evaluated what to do now that synoptic reports exist. The goal of the group was to achieve a consensus definition of nodal count for the STS GTSD that is clinically justifiable, reasonable for data managers, and reliable.

We reviewed:

- 1. Pathology reports submitted by data managers
- 2. Data on the prevalence of mediastinoscopy prior to surgical resection

Summary of Recommendations:

1. Nodes harvested during mediastinoscopy performed either at prior separate setting or during same anesthetic as the lung resection be included in final nodal count

2. Nodes sampled prior to induction therapy of any kind (chemo, XRT, and/or IO) are NOT included in final surgical nodal counts

3. Preoperative EBUS (performed either at a separate setting or during the same anesthetic) are NOT included in final surgical resection nodal count

## An Example

SYNOPTIC REPORTING	-	Additional Lymph Node Procedures	
LUNG 8th Edition - Protocol posted: 4/29/2020		Procedure Description	Lymph Node Resection
SPECIMEN		Procedure Identifier	S21-070642
Procedure	Pneumonectomy	Procedure Date / Time	10/4/2021
Specimen Laterality	Right	Number of Lymph Nodes Involved	20
TUMOR		Nodal Stations Involved	4R: Lower paratracheal
Tumor Site	Upper lobe of lung	-	10R: Hilar
Histologic Type	Invasive adenocarcinoma, micropapillary		7: Subcarinal
	predominant	Extranodal Extension	Present
Other Subtypes Present Histologic Grade	Papillary (<5%) G3: Poorly differentiated	Number of Lymph Nodes Examined	23
Total Tumor Size (size of entire tumor)	Greatest Dimension (Centimeters): 3.7 cm	Nodal Stations Examined	4R: Lower paratracheal
Additional Dimension (Centimeters)	2.9 cm		8R: Para-esophageal (below carina)
	2.2 cm		9R: Pulmonary ligament
Tumor Focality	Single focus		10R: Hilar
Visceral Pleura Invasion	Present		7: Subcarinal
Direct Invasion of Adjacent Structures Treatment Effect	No adjacent structures present Greater than 10% residual viable tumor		, i carca ma
Lymphovascular Invasion	Present	PATHOLOGIC STAGE CLASSIFICATION (pTNM, A	JCC 8th Edition)
	Lymphatic		
	Venous	TNM Descriptors	y (post-treatment)
MARGINS		Primary Tumor (pT)	pT2a
Margins		Regional Lymph Nodes (pN)	pN2
Bronchial Margin	Uninvolved by invasive carcinoma	0 / 1 (1 /	
Vascular Margin Parenchymal Margin	Uninvolved by carcinoma Not applicable	Comment(s)	
a choryman wargin	Hot approade	Comment(s)	This form incorporates lymph nodes from the
			previous resection case, S21-70642. Block D4 for

ancillary testing

1. Does this path report include nodes from a prior resection? Yes.

2. Did the patient have treatment between the mediastinoscopy and the lung resection? The patient did have pre-resection treatment (note the pathological 'y'). Not enough information here to determine WHEN the treatment occurred. If the treatment occurred prior to the mediastinoscopy, the nodes would not be included.

# Why aren't nodes from EBUS counted?

It is impossible to completely resect a lymph node during an EBUS, however a lymph node removed during a mediastinoscopy can't be 're-resected'. What other sequences does this potentially impact?

SeqNo: 2020 Long Name: Number of Malignant Nodes Short Name: NumMaligNodes Format: Integer Definition: Indicate the number of malignant nodes. Low Value: 0 High Value: 60 Lung Cancer Nodes Assessed ParentLongName: ParentShortName: LungNodeAsses ParentValue: ParentHarvestCodes: = "Yes"

Intent/Clarification: Indicate the total number of malignant nodes. This is not the same as the number of malignant nodal stations.


Total number of malignant nodes will be listed on your <u>final pathology report</u>. Use the final pathology report from the day of surgery (resection) for the number of malignant nodes.

SeqNo: Long Nam Short Nam Format:		Lung Cancer - Number of Nodes LungCANodes Integer
Definition	:	Indicate the total number of nodes sampled/harvested.
Low Value	e: 1	High Value: 60
ParentLon ParentSho ParentVal ParentHar	rtName:	Lung Cancer Nodes Assessed LungNodeAsses 1 = "Yes"

Intent/Clarification: Indicate the total number of nodes sampled. This is not the same as number of nodal stations.

SeqNo: 2040 Long Name: Short Name: Format:	Pathologic Staging - Lung Cancer - N PathStageLungN Text (categorical values specified by STS)
Definition:	Indicate the appropriate descriptor for the lung cancer regional nodes based on final pathology report.
ParentLongName: ParentShortName: ParentValue: ParentHarvestCodes:	Lung Cancer Nodes Assessed LungNodeAsses 1 = "Yes"

## IQVIA Update Joe Brower



#### IQVIA Update

Please note: Submitted tickets are currently under review and the IQVIA support team will follow up on resolution and/or target release confirmation. The IQVIA Team is currently reviewing items to be targeted for an upcoming release. Those items will be posted to the Notifications section.

Analysis Report Questions

- Please contact IQVIA
   Support
  - gtsdtechsupport@iqvia.com

 STS/Research Center will be looped in as needed when tickets are escalated to Tier 2

#### Contact Information

Leigh Ann Jones, STS National Database Manager, Congenital and General Thoracic

#### Database Operational Questions

Ljones@sts.org
312-202-5822

STSDB@sts.org

## Upcoming GTSD Webinars

# Monthly Webinar

•July 13 @ 1:30CT

# User Group Call

•July 27 @ 2:30CT



### **Open Discussion**



PLEASE USE THE Q&A FUNCTION.

WE WILL ANSWER AS MANY QUESTIONS AS POSSIBLE. WE ENCOURAGE YOUR FEEDBACK AND WANT TO HEAR FROM YOU!

## **STS** National Database<sup>™</sup>

Trusted. Transformed. Real-Time.

## THANK YOU FOR JOINING!